HLA-A*0201 GP100 complex Protein, Human (Biotinylated, IMDQVPFSV, HEK293, Avi-His)

B2M is a component of MHC class I complexes that present peptide antigens to the immune system. HLA-A*0201 GP100 complex Protein, Human (Biotinylated, IMDQVPFSV, HEK293, Avi-His) is a recombinant protein dimer complex containing human-derived HLA-A*0201 GP100 complex protein, expressed by HEK293 , with C-Avi, C-10*His labeled tag.

B2M, or Beta-2-microglobulin, functions as a critical component of the class I major histocompatibility complex (MHC), playing a central role in presenting peptide antigens to the immune system. Notably, exogenously applied M. tuberculosis EsxA or EsxA-EsxB binds B2M and reduces its export to the cell surface, potentially leading to defects in class I antigen presentation. B2M exists as a heterodimer, composed of an alpha chain and a beta chain, with the latter serving as the beta-chain of major histocompatibility complex class I molecules. Polymers of B2M have been observed in tissues of patients on long-term hemodialysis. B2M, in its isolated form, interacts with M. tuberculosis EsxA and an EsxA-EsxB complex, forming a tripartite complex detectable in the host endoplasmic reticulum. The stability of the B2M-EsxA complex extends across a broad pH range and in the presence of high salt concentrations. Additionally, B2M forms heterotrimers with HLA-E, HLA-G, and HLA-F, along with a self- or foreign peptide, contributing to the diverse functions of the major histocompatibility complex. Furthermore, B2M engages in a heterotrimeric complex with MR1, playing a role in antigen presentation associated with metabolite antigens.

Human

HEK293

C-Avi;C-10*His

P01892 (G25-I308, A269V)&P61769 (I21-M119)&IMDQVPFSV

3105  [NCBI]&567  [NCBI]

IQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHVTLSQPKIVKWDRDM&GSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYWDQETRNVKAQSQTDRVDLGTLRGYYNQSEAGSHTIQIMYGCDVGSDGRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITKRKWEAAHEAEQLRAYLDGTCVEWLRRYLENGKETLQRTDPPKTHMTHHPISDHEATLRCWALGFYPAEITLTWQRDGEDQTQDTELVETRPAGDGTFQKWAAVVVPSGEEQRYTCHVQHEGLPKPLTLRWELSSQPTIPI

55-60 kDa

Greater than 95% as determined by reducing SDS-PAGE.

<1 EU/μg, determined by LAL method.